This is a Pre-Publication Offer. Available now for $2,995 Price will increase to $3,500 on Oct. 5th. Save $505!!

The World Health Organization has identified a group of diseases that are the world's most pressing health problems. This represents an opportunity for test manufacturers, particularly in POC testing. Because of their ability to deliver fast results at the point of care, rapid testing is a focus area of healthcare providers and payors in infectious disease prevention. Kalorama Information has been reporting on the rapid test area for several years and has identified the segments with fastest growth, and infectious disease has surfaced as one of those segments.

This report, Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations), examines this POC segment with a focus on new threats for which there are markets in the developing world and in developed countries.


A Unique Approach: Market and Technical Analysis
Tests can only be marketed if they can be manufactured and if they can function in the healthcare environment. Thus, this report also discusses the technical choices, possibilities and limitations to today's POC tests especially when they are used in the developing world. Reagent issues, testing on strips, instrumented and non-instrumented tests are coved in this report. These factors will impact what tests will reach the market and how they will function.

Kalorama Information has been reporting on the rapid test area for several years and has identified the segments with fastest growth, and infectious disease has surfaced as one of those segments. This report, Point of Care Diagnostics for Emerging Infectious Disease Threats (Market Analysis and Technical Considerations), examines this segment, and especially new threats for which there are large markets in the developing world and in developed countries.

An Opportunity For Test Makers

Infectious disease is a broad category, and in some disease areas, diagnostic companies already own market share. Increasingly hospitals and clinics are seeing new infectious disease threats and tests are being developed to assist them. Within the infectious disease testing market, this report details the opportunities that could be found when diseases of the developing world enter the healthcare system of the developed. This report provides market projections for point of care diagnostics in the developed and developing world for the following infectious diseases:

Chagas Disease, Rapid Test Market Forecast to 2015
Chikungunya, Rapid Test Market Forecast to 2015
Dengue Fever, Rapid Test Market Forecast to 2015
HIV, Rapid Test Market Current Size and Forecast to 2015
HPV, Rapid Test Market Current Size and Forecast to 2015
Leishmaniasis, Rapid Test Market Forecast to 2015
Onchocerciasis (River Blindness), Rapid Test Market Forecast to 2015
STDs, Rapid Test Market Current Size and Forecast to 2015
Tuberculosis, Rapid Test Market Forecast to 2015
In addition the report also provides:
The Overall Point of Care Diagnostics Market
Economics of Financial and International Programs
Company Profiles of Leaders in the POC Infectious Disease Market
Key Players in the Infectious Disease Rapid Test Market
Developed and Developing World Opportunities
Test Volumes in Developing Countries
Economics of Financial and International Programs
Review of Test Products Currently on the Market
Climate, Water Use and Sample Prep Considerations
Overall POC Diagnostics Market Statistics
EMR and Connectivity Issues
Tests in Development
The Role of Drug Resistance
Disease Statistics
POC and Infrastructure Needs
Comparison of Test Modalities and Sample Collection Methods

Two Industry Experts Provide Unique Insights

Shara Rosen is Kalorama Information’s lead diagnostic industry analyst. She is the author of seven best-selling editions of The Worldwide Market for In Vitro Diagnostics, as well as scores of other titles on segments of the IVD Industry.

Brendan O'Farrell is the President of Diagnostic Consulting Network (www.dcndx.com), a provider of OEM services to developers and manufacturers of rapid assays. Key services include contract rapid assay system development, custom reagent development, industry education and training and consulting services. Among the topics these experts discuss is the number of competitors who have been successful with efforts in developing countries. The following companies are discussed in this report:

3QBD
Abbott Diagnostics Access Bio, Inc.
Acon Laboratories, Inc./Innovacon
Akers Biosciences, Inc.
Akonni Biosystems Inc.
Alere
American Bionostica, Inc.
AT First Diagnostic LLC
Beckman Coulter Inc. Becton Dickinson
Bhat Bio-tech India (p) Ltd.
Biocan Diagnostics Inc.
bioLytical Laboratories
Biomagnetics Diagnostics Corp.
Bio-Manguinhos/FioCruz
bioMerieux
BioVei Incorporated
Burnet Institute
California Institute of Technology (Caltech)
CapitalBio Corporation
Catalysis Foundation for Health
Cellestis Ltd
Cepheid
Chembio Diagnostic Systems, Inc.
Clearbridge BioLoc
Clinoteck Diagnostics
Core Diagnostics
CTK Biotech Inc.
Diagnostics for All (DFA)
Diagnostics for the Real World (DRW)
DIALAB
DNA Medicine Institute (DMI)
Eiken Chemical Co., Ltd.
Enigma Diagnostics Limited
Epistem Plc
FK Biotecnologia
Guardian Technologies International
Hain Lifescience GmbH
Hema Diagnostic Systems (HDS)
i+MED Laboratories Company Limited
InBios International, Inc.
Ionian Technologies, Inc.
IQuum Inc.
Jal Innovation (S) Pte
LabNow
Lifeassay Diagnostics (Pty) Ltd
Linnodee Ltd.
LumiQuick Diagnostics, Inc.
J. Mitra & Co. Pvt Ltd
MP Biomedicals
MedMira Inc.
Micronics, Inc.
Microskia
Millennium Biotechnology, Inc. (MBI)
Omega Diagnostics Group PLC
Partec GmbH
PointCare Technologies, Inc.
QBC Diagnostics, Inc.
QuantuMDx Group
Premier Medical Corporation Limited
Princeton BioMeditech Corporation
Seventh Sense Biosystems, Inc.
Signature Mapping Medical Sciences, Inc.
Span Diagnostics Ltd.
Standard Diagnostics, Inc.
Tulip Group
VEDA.LAB
Veredus Laboratories Pte
WAMA Diagnostica
Zyomyx Inc.

CHAPTER ONE: EXECUTIVE SUMMARY

Scope and Methodology
Emerging Market Trends, diseases and technologies
World Demand for Decentralized Testing for Infectious Diseases

CHAPTER TWO: COMMERCIALIZATION OF DECENTRALIZED TEST DEVICES FOR INFECTIOUS DISEASES

Overview
User Training and Support Services
Connectivity Supports Decentralized Testing
The Disease Burden
Drug Resistance Complicates the Test Landscape
An Unmet Need
Economics of Financial and International Programs
Conclusion

CHAPTER THREE: TECHNICAL CONSIDERATIONS

Overview
Reagent Issues
Instrumented or non-instrumented
Diagnostics on Paper Test Strips
The Promise of Decentralized Molecular Diagnostics
Wireless Communication
Miniaturization

CHAPTER FOUR: CHAGAS DISEASE

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER FIVE: CHIKUNGUNYA

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER SIX: DENGUE

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER SEVEN: HIV

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER EIGHT: HPV

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER NINE: LEISHMANIASIS

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER TEN: LEPTOSPIROSIS

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER ELEVEN: MALARIA

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER TWELVE: ONCHOCERCIASIS (RIVER BLINDNESS)

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER THIRTEEN: STDs

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future

CHAPTER FOURTEEN: TUBERCULOSIS

Introduction: Key Comment
Geographic Markets
International Programs
Status quo in testing
Players
Test technologies, now and future